A novel class of sodium/calcium exchanger inhibitor: Design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 11, 2005, Pages 3721-3735

  Hasegawa, Hirohiko ^a   Muraoka, Masami ^a   Ohmori, Mikiko ^a   Matsui, Kazuki ^a   Kojima, Atsuyuki ^b  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b Sumika Technoservice Corporation   (Japan)

Author keywords

3,4 Dihydro 2(1H) quinazolinone derivative; Ischemic reperfusion injury; Na+ Ca2+ exchanger; Sodium calcium exchanger

Indexed keywords

2,2,2 TRICHLORO N [2 (2 NAPHTHYLCARBONYL)PHENYL]ACETAMIDE; 2,2,2 TRICHLORO N [2 (2 PYRIDYLCARBONYL)PHENYL]ACETAMIDE; 2,2,2 TRICHLORO N [2 (2 THIENYLCARBONYL)PHENYL]ACETAMIDE; 2,2,2 TRICHLORO N [2 (3 BENZYLOXYBENZOYL)PHENYL]ACETAMIDE; 2,2,2 TRICHLORO N [2 (3 CHLOROBENZOYL)PHENYL]ACETAMIDE; 2,2,2 TRICHLORO N [2 (3 METHOXYBENZOYL)PHENYL]ACETAMIDE; 2,2,2 TRICHLORO N [2 (3 METHYLBENZOYL)PHENYL]ACETAMIDE; 2,2,2 TRICHLORO N [2 (4 METHYLBENZOYL)PHENYL]ACETAMIDE; 2,2,2 TRICHLORO N [2 (BENZYLCARBONYL)PHENYL]ACETAMIDE; 2,2,2 TRICHLORO N [2 (CYCLOHEXYLCARBONYL)PHENYL]ACETAMIDE; 2,2,2 TRICHLORO N [2 (ISOPROPYLCARBONYL)PHENYL]ACETAMIDE; 2,2,2 TRICHLORO N [4 CHLORO 2 (2 FUROYL)PHENYL]ACETAMIDE; 3 (1 BENZYLPIPERIDIN 4 YL) 4 PHENYL 3,4 DIHYDROQUINAZOLIN 2(1H) ONE MONOCITRATE; 3 (2 ETHOXYETHYL) 4 PHENYL 4 (TRICHLOROMETHYL) 3,4 DIHYDROQUINAZOLIN 2(1H) ONE; 3 (4 METHYLPENTYL) 4 PHENYL 4 (TRICHLOROMETHYL) 3,4 DIHYDROQUINAZOLIN 2(1H) ONE; 3 [3 (DIMETHYLAMINO)PROPYL] 4 (2 NAPHTHYL) 4 (TRICHLOROMETHYL) 3,4 DIHYDROQUINAZOLIN 2(1H) ONE; 3 [3 (DIMETHYLAMINO)PROPYL] 4 (2 PYRIDYL) 4 (TRICHLOROMETHYL) 3,4 DIHYDROQUINAZOLIN 2(1H) ONE; 3 [3 (DIMETHYLAMINO)PROPYL] 4 (2 THIENYL) 4 (TRICHLOROMETHYL) 3,4 DIHYDROQUINAZOLIN 2(1H) ONE; 3 [3 (DIMETHYLAMINO)PROPYL] 4 ISOPROPYL 4 (TRICHLOROMETHYL) 3,4 DIHYDROQUINAZOLIN 2(1H) ONE; 3 [3 (DIMETHYLAMINO)PROPYL] 4 METHYL 4 (TRICHLOROMETHYL) 3,4 DIHYDROQUINAZOLIN 2(1H) ONE; 3 [3 (DIMETHYLAMINO)PROPYL] 4 PHENYL 4 (TRICHLOROMETHYL) 3,4 DIHYDROQUINAZOLIN 2(1H) ONE; 4 BENZYL 3 [3 (DIMETHYLAMINO)PROPYL] 4 (TRICHLOROMETHYL) 3,4 DIHYDROQUINAZOLIN 2(1H) ONE; 5 CHLORO 2 TRICHLOROACETYLAMINOBENZOPHENONE; 6 CHLORO 3 [3 (DIMETHYLAMINO)PROPYL] 4 (2 FURYL) 4 (TRICHLOROMETHYL) 3,4 DIHYDROQUINAZOLIN 2(1H) ONE; 6 CHLORO 3 [3 (DIMETHYLAMINO)PROPYL] 4 PHENYL 4 (TRICHLOROMETHYL) 3,4 DIHYDROQUINAZOLIN 2(1H) ONE; 6 CYCLOHEXYL 3 [3 (DIMETHYLAMINO)PROPYL] 4 (TRICHLOROMETHYL) 3,4 DIHYDROQUINAZOLIN 2(1H) ONE; N (2 ACETYLPHENYL) 2,2,2 TRICHLOROACETAMIDE; N (2 BENZOYLPHENYL) 2,2,2 TRICHLOROACETAMIDE; QUINAZOLINE DERIVATIVE; SM 15811; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CELL PROTECTION; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; NONHUMAN; SODIUM CALCIUM EXCHANGE; STRUCTURE ACTIVITY RELATION;

EID: 18144394759     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.03.019     Document Type: Article

References (33)

1. W.G. Nayler, and J.S. Elz Circulation 74 1986 215
2. M. Tani Annu. Rev. Physiol. 52 1990 543
3. L.H. Opie Cardiovasc. Drugs Ther. 5 1991 237
4. 2+ exchanger: M.P. Blaustein, and W.J. Lederer Physiol. Rev. 79 1999 763
5. M.H. Akabas Mol. Pharmacol. 66 2004 8
6. P.M. Grinwald J. Mol. Cell. Cardiol. 14 1982 359
7. D.G. Renlund, G. Gerstenblith, E.G. Lakatta, W.E. Jacobs, C.H. Kallman, and M.L. Weisfeldt J. Mol. Cell. Cardiol. 16 1984 795
8. M. Tani, and J.R. Neely Circ. Res. 65 1989 1045
9. J.G. Murphy, T.W. Smith, and J.D. Marsh Am. J. Physiol. 254 1988 H1133
10. D. Khananshvili, D.C. Price, M.J. Greenberg, and Y. Sarne J. Biol. Chem. 268 1993 200
11. L. Brown, E.J. Cragoe Jr., K.C. Abel, S.W. Manley, and J.R. Bourke Arch. Pharmacol. 344 1991 220
12. F. Rogister, D. Laekmann, P. Plasman, V. Eylen, M. Ghyoot, C. Maggetto, J. Liegeois, J. Geczy, A. Herchuelz, J. Delarge, and B. Masereel Eur. J. Med. Chem. 36 2001 597
13. T. Iwamoto, T. Watano, and M. Shigekawa J. Biol. Chem. 271 1996 22391
14. T. Watano, J. Kimura, T. Morita, and H. Nakanishi Br. J. Pharmcol. 119 1996 555
15. T. Matsuda, N. Arakawa, K. Takuma, Yoko Kishida, Y. Kawasaki, M. Sakaue, K. Takahasi, T. Takahashi, T. Suzuki, T. Ota, A.H. Takahasi, M. Onishi, Y. Tanaka, K. Kameo, and A. Baba J. Pharmacol. Exp. Ther. 298 2001 249
16. H. Tanaka, K. Nishimaru, T. Aikawa, W. Hirayama, Y. Tanaka, and K. Shigenobu Br. J. Pharmcol. 135 2002 1096
17. T. Kuramochi, A. Kakefuda, H. Yamada, I. Sato, T. Taguchi, and S. Sakamoto Bioorg. Med. Chem. 12 2004 5039
18. T. Iwamoto, Y. Inoue, K. Ito, T. Sakaue, S. Kita, and T. Katsuragi Mol. Pharmacol. 66 2004 45
19. M. Yamamoto, and H. Yamamoto Chem. Pharm. Bull. 29 1981 2135
20. The compound 13c was synthesized according to Ref. 13. The compounds 13d, 13g-j were synthesized according to Ref. 14. The compound 13l was synthesized according to Ref. 15. The compounds 13k-o were synthesized according to Ref. 16
21. Berger, L.; Stempel, A.; Sternbach, L. H.; Wenis, E.; Fryer, R. I.; Schmidt, R. A. Belg. Patent 619,101, 1962
22. Chem. Abstr. 59 1963 10092
23. F. Hunziker, R. Fischer, P. Kipfer, J. Schmutz, H.R. Burki, E. Eichenberger, and T.G. White Eur. J. Med. Chem. 16 1981 391
24. N.N. Goldberg, L.B. Barkley, and R. Levine J. Am. Chem. Soc. 73 1951 4301
25. H. Yamamoto, C. Saito, S. Inaba, H. Awata, M. Yamamoto, Y. Sakai, and T. Komatsu Arzneim.-Forsch 23 1973 1266
26. D.W. Ockenden, and K. Schofield J. Chem. Soc. 1953 3440
27. S.V. Frye, M.C. Johnson, and N.L. Valvano J. Org. Chem. 56 1991 3750
28. Alkyl halides and aldehydes used for N-alkylation were listed in Table 7
29. S. Yamamoto, K. Matsui, M. Kitano, and N. Ohashi J. Cardiovasc. Pharm. 35 2000 855 The method of the evaluation system is cited therein
30. +-free HEPES buffered medium
31. R.A. Chapman, A. Coray, and J.A.S. Mcguigan J. Physiol. (London) 343 1983 253
32. a ver. 6.0. Advanved Chemistry Development: Toronto, Ontario, Canada
33. L.V. Hryshko, and K.D. Philipson Basic Res. Cardiol. 92 Suppl. 1 1997 45